EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Starton Therapeutics's Enterprise Value is $0.00 Mil.
Starton Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-2.29 Mil. Therefore, Starton Therapeutics's EV-to-FCF for today is 0.00.
The historical rank and industry rank for Starton Therapeutics's EV-to-FCF or its related term are showing as below:
STA's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 8.405 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Starton Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Starton Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Starton Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starton Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Starton Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Starton Therapeutics's EV-to-FCF falls into.
Starton Therapeutics's current Enterprise Value is $0.00 Mil.
Starton Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Starton Therapeutics's PE Ratio for today is calculated as:
Starton Therapeutics's share price for today is $0.00.
Starton Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Starton Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Starton Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Starton Therapeutics (Starton Therapeutics) Business Description
Starton Therapeutics Inc is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, and longer. Starton's proprietary continuous delivery technology can increase the efficacy of approved drugs, make them more tolerable, and expand their potential use.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STA has been successfully added to your